Inflammatory biomarkers of coronary heart disease

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Review

Hongyu Li¹, Kai Sun², Ruiping Zhao^1,*, Jiang Hu³, Zhiru Hao¹, Fei Wang¹, Yaojun Lu¹, Fu Liu¹, Yong Zhang¹

Show Less

¹ Department of Cardiology, Baotou Central Hospital, Baotou, China

² Department of Radiology, Baotou Central Hospital, Baotou, China

³ Department of Surgery, Baotou Central Hospital, Baotou, China

Front. Biosci. (Landmark Ed) 2017, 22(3), 504–515; https://doi.org/10.2741/4498

Published: 1 January 2017

(This article belongs to the Special Issue Cellular immunology and stem cell biology)

Download PDF

Cite

Abstract

Coronary heart disease (CHD), characterized by inflammation and accumulation of plaques mainly comprised of lipids, calcium and inflammatory cells in the walls of coronary arteries. CHD is exacerbated by specific cardiovascular risk factors, such as obesity, diabetes mellitus, and hypertension. The current review focuses on the critical role of traditional inflammatory biomarkers, including interleukin-6, C-reactive protein (CRP), complement, CD40 and myeloperoxidase (MPO), in the pathogenesis of CHD.

Keywords

Coronary heart disease

atherosclerosis

inflammation

C-reactive protein

review

Previous article in this issue

Next article in this issue

Front. Biosci. (Landmark Ed) Print ISSN 2768-6701 Electronic ISSN 2768-6698